Macrocyclic lactams
Compounds represented by the following structure (I), acid-addition salts and pro-drugs are disclosed: wherein the ring structure includes no substitutions, one substitution, or more than one substitution; and wherein n is equal to an integer grater than 1, preferably 2, 3, or 4; m is equal to a positive integer, preferably 1, 2 or 3, and each separate X n and X are each separately selected from a nucleophilic residue, preferably —H, —OH, —O—CO-alkyl, —O-alkyl, —NH 2 , a halogen and the like; and wherein the dashed line represents a C—C bond or a C—H bond, and the dashed and solid line represents either a carbon-carbon single bond or a carbon-carbon double bond.
1. A substantially purified compound having the following structure:
or its acid-addition salts or its pro-drug esters.
2. A method of treating an individual with cancer, comprising:
administering to the individual a compound of claim 1 , its acid-addition salts or its pro-drug esters, wherein the cancer is selected from the group consisting of an adenocarcinoma colon cancer, a prostate cancer, a T-cell leukemia, and a melanoma cancer.
3. A method of treating cancer comprising the step of contacting a cancer cell with a compound of claim 1 , wherein the cancer is selected from the group consisting of an adenocarcinoma colon cancer, a prostate cancer, a T-cell leukemia, and a melanoma cancer.
4. The method of claim 3 , wherein the cancer is an adenocarcinoma colon cancer.
5. The method of claim 3 , wherein the cancer is a prostate cancer.
6. The method of claim 3 , wherein the cancer is a T-cell leukemia.
7. The method of claim 3 , wherein the cancer is a melanoma cancer.
8. The method of claim 2 , wherein the cancer is an adenocarcinoma colon cancer.
9. The method of claim 2 , wherein the cancer is a prostate cancer.
10. The method of claim 2 , wherein the cancer is a T-cell leukemia.
11. The method of claim 2 , wherein the cancer is a melanoma cancer.
12. The method of claim 2 , wherein the compound is administered with a pharmaceutically acceptable carrier, diluent, or excipient.
13. A method of treating an individual with cancer, comprising administering to the individual a composition comprising the compound of claim 1 , an acid-addition salt thereof, or a pro-drug ester therof, wherein the cancer is selected from the group consisting of an adenocarcinoma colon cancer, a prostate cancer, a T-cell leukemia, and a melanoma cancer.
14. The method of claim 13 , wherein the composition is administered with a pharmaceutically acceptable carrier, diluent, or excipient.
15. The method of claim 13 , wherein the cancer is an adenocarcinoma colon cancer.
16. The method of claim 13 , wherein the cancer is a prostate cancer.
17. The method of claim 13 , wherein the cancer is a T-cell leukemia.
18. The method of claim 13 , wherein the cancer is a melanoma cancer.